Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
Coussy F, Deluche E, Pistilli B, Ladoire S, Ferrero JM, Cottu P. Coussy F, et al. Among authors: cottu p. Bull Cancer. 2021 Sep;108(9):843-854. doi: 10.1016/j.bulcan.2021.04.007. Epub 2021 Jun 19. Bull Cancer. 2021. PMID: 34154797 Free article. Review. French.
[Clinical activity spectrum of irinotecan].
Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. Cottu PH, et al. Bull Cancer. 1998 Dec;Spec No:21-5. Bull Cancer. 1998. PMID: 9932080 Free article. Review. French.
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J; Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM, et al. Among authors: cottu p. J Clin Oncol. 2003 Nov 1;21(21):3987-94. doi: 10.1200/JCO.2003.02.073. J Clin Oncol. 2003. PMID: 14581421 Clinical Trial.
[Biomarkers of endocrine therapy-resistance in breast cancers].
de Cremoux P, Debled M, Bonnefoi H, Cottu P. de Cremoux P, et al. Among authors: cottu p. Bull Cancer. 2010 Aug;97(8):951-63. doi: 10.1684/bdc.2010.1137. Bull Cancer. 2010. PMID: 20605764 Free article. Review. French.
Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.
Helissey C, Berger F, Cottu P, Diéras V, Mignot L, Servois V, Bouleuc C, Asselain B, Pelissier S, Vaucher I, Pierga JY, Bidard FC. Helissey C, et al. Among authors: cottu p. Cancer Lett. 2015 May 1;360(2):213-8. doi: 10.1016/j.canlet.2015.02.010. Epub 2015 Feb 17. Cancer Lett. 2015. PMID: 25700777 Clinical Trial.
[New options in adjuvant endocrine therapy in breast cancer].
Saltel-Fulero A, Donnadieu A, Leman-Detours S, Cottu P. Saltel-Fulero A, et al. Among authors: cottu p. Bull Cancer. 2016 Jan;103(1):104-12. doi: 10.1016/j.bulcan.2015.10.011. Epub 2015 Dec 7. Bull Cancer. 2016. PMID: 26675809 Review. French.
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A. Bonnefoi H, et al. Among authors: cottu p. Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18. Ann Oncol. 2016. PMID: 27052658 Free article. Clinical Trial.
279 results